Type
Internal restructuring
Country
Ireland
Region
Ireland; Southern; South-West
Location of affected unit(s)
Ringaskiddy (Co Cork)
Sector
Manufacturing
(20 - 21) Manufacture of chemicals and pharmaceuticals
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations

102 jobs
Number of planned job losses
Job loss
Announcement Date
23 April 2026
Employment effect (start)
1 October 2026
Foreseen end date
31 December 2026

Description

Pfizer, an American pharmaceutical multinational, announced 102 voluntary redundancies at its manufacturing plant in Ringaskiddy, Co Cork, Ireland.

The cuts stem from patents for key drugs ending, reducing production demand, and aligning with long-term business objectives. SIPTU, the local union, has requested an urgent meeting with management after the announcement. The union represents about 300-400 members at the site. The plant employs about 800 people, meaning the job cuts represent roughly 12% of the workforce at that site. Job cuts will be in the form of redundancy and will take effect in the fourth quarter of 2026.

In total Pfizer employs some 4,500 people in Ireland. Other Pfizer sites in Newbridge and Dublin remain unaffected.

Last year Pfizer cut 210 jobs in Ireland as the result of its global $1.5 billion cost-cutting programme: Pfizer 2024 - Ireland.


Citation

Eurofound (2026), Pfizer, Internal restructuring in Ireland, factsheet number 300376, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/300376.